Literature DB >> 16971731

Patient-specific dendritic-cell vaccines for metastatic melanoma.

Robert O Dillman, Senthamil R Selvan, Patric M Schiltz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16971731     DOI： 10.1056/NEJMc061667

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Dendritic cell vaccines for melanoma: past, present and future.

Authors:  Robert O Dillman; Gabriel I Nistor; Andrew N Cornforth
Journal:  Melanoma Manag       Date:  2016-11-29

Review 2.  An update on the relevance of vaccine research for the treatment of metastatic melanoma.

Authors:  Robert O Dillman
Journal:  Melanoma Manag       Date:  2017-11-23

3.  Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy.

Authors:  Andrew N Cornforth; Gregory J Lee; Abner W Fowler; Denysha J Carbonell; Robert O Dillman
Journal:  J Clin Immunol       Date:  2009-05-07       Impact factor: 8.317

4.  KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Authors:  Mojca Skoberne; Alice Yewdall; Keith S Bahjat; Emmanuelle Godefroy; Peter Lauer; Edward Lemmens; Weiqun Liu; Will Luckett; Meredith Leong; Thomas W Dubensky; Dirk G Brockstedt; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2008-11-06       Impact factor: 14.808

5.  Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.

Authors:  Robert O Dillman; Edward F McClay; Neil M Barth; Thomas T Amatruda; Lee S Schwartzberg; Khosrow Mahdavi; Cristina de Leon; Robin E Ellis; Carol DePriest
Journal:  Cancer Biother Radiopharm       Date:  2015-06       Impact factor: 3.099

Review 6.  Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma.

Authors:  Robert O Dillman; Andrew N Cornforth; Edward F McClay; Carol Depriest
Journal:  Melanoma Manag       Date:  2019-05-31

7.  Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment.

Authors:  Robert Owen Dillman; Candace Hsieh
Journal:  Biomedicines       Date:  2019-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.